Conflict of interest: Nothing to report
Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders†
Article first published online: 15 FEB 2011
Copyright © 2011 Wiley-Liss, Inc.
American Journal of Hematology
Volume 86, Issue 3, pages 278–291, March 2011
How to Cite
Dierickx, D., Delannoy, A., Saja, K., Verhoef, G. and Provan, D. (2011), Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am. J. Hematol., 86: 278–291. doi: 10.1002/ajh.21939
- Issue published online: 23 FEB 2011
- Article first published online: 15 FEB 2011
- Accepted manuscript online: 29 NOV 2010 12:15PM EST
- Manuscript Accepted: 16 NOV 2010
- Manuscript Revised: 15 NOV 2010
- Manuscript Received: 19 OCT 2010
Autoimmune hematological disorders encompass a broad group of hematological conditions characterized by the loss of self-tolerance to a variety of antigens. Despite good response to first-line therapy in the majority of patients, relapses are common, necessitating new and safe therapeutic options. The anti-CD20 monoclonal antibody rituximab has led to substantial improvement in the treatment of malignant and immune-mediated disorders involving B cells. Although experience with rituximab in immune-mediated hematological disorders is rarely supported by randomized trials, there is now substantial experience with rituximab suggesting that anti-CD20 therapy is an effective and well-tolerated alternative to immunosuppressive therapy in these disorders. However, caution is needed based on recent reports describing—sometimes severe—rituximab-related complications. Am. J. Hematol. 2011. © 2011 Wiley-Liss, Inc.